MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / ...

Explore how AI-powered wireless implants could replace opioids, using ultrasonic energy to block chronic pain signals without addiction risk.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States.

In This Article, You'll Discover Understanding how NerveFreedom's unique formulation addresses multiple aspects of ner ...

As people age, their risk of developing type 2 diabetes increases. In fact, age is one of the most important risk factors for ...

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from an existing customer in the United States. The customer is an experienced user of the Nexstim therapy ...

C7 neurotomy added to standard speech therapy enhances language recovery in patients with chronic post-stroke aphasia, a randomized trial suggests.

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...

Shares of Artelo Biosciences, Inc. (ARTL) more than doubled on Monday after the company announced favorable results from its ...

Shares of Artelo Biosciences rose after the company reported positive data for its first in-human trial for a potential non-opioid treatment for persistent pain. The stock more than doubled to $16.30 ...